AbbVie (NYSE: ABBV) reported a rise in web earnings for the second quarter of fiscal 2026, aided by robust income development. The numbers topped expectations.
Worldwide web revenues rose to $16.99 billion within the second quarter from $15.42 billion within the prior-year quarter, surpassing analysts’ estimates. Revenues elevated 10.2% on a reported foundation and 9.5% on an operational foundation.
Web earnings attributable to the corporate was $3.61 billion or $2.03 per share within the second quarter, in comparison with $938 million or $0.52 per share a yr earlier. On an adjusted foundation, Q2 earnings moved as much as $3.65 per share from $2.97 per share within the year-ago quarter. Earnings beat estimates.
“AbbVie delivered one other glorious quarter, marked by excellent execution and pipeline development. We additionally introduced the proposed acquisition of Apogee Therapeutics, which strengthens our potential to ship modern medicines to sufferers, bolsters our immunology management and creates vital shareholder worth,” stated Robert Michael, AbbVie’s CEO.
